Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05678998 · ClinicalTrials.gov registry record · Phase 1
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by Werewolf Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT05678998 is a Phase 1 study that has completed, run by Werewolf Therapeutics. The registered enrollment target is 25 participants.
The verdict
NCT05678998, a Phase 1 study, has completed, sponsored by Werewolf Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
Interventions
- DRUG WTX-330
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-12-06 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05678998
The ClinicalTrials.gov registry entry for NCT05678998 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Werewolf Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which WTX-330 is the first listed.
NCT05678998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05678998 about?
NCT05678998 is a clinical study titled "WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma". A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
What is the current status of trial NCT05678998?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2022-12-06. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT05678998?
The interventions under investigation include: WTX-330 (DRUG).
Who is sponsoring clinical trial NCT05678998?
This trial is sponsored by Werewolf Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.